BioSpace News Archive

Castle Biosciences Presents New Data on the Validity and Accuracy of DecisionDx-Melanoma in Patients With T1 Cutaneous Melanoma Tumors at the 19 th Annual South Beach Symposium Additional Virtual Posters Highlight Data on DecisionDx® DiffDx™-Melanoma and DecisionDx®-SCC

Veeva Systems announced that 6 out of the top 7 global CROs have joined the Veeva Vault CDMS partner program.

Acceleron Announces Fourth Quarter and Full Year 2020 REBLOZYL ® Net Sales - Acceleron expects to report approximately $23.0 million in royalty revenue for Q4 2020 from approximately $115 million in net sales of REBLOZYL ® (luspatercept-aamt) as reported by Bristol Myers Squibb -

Olympus, a global technology leader in designing and delivering innovative solutions for medical and surgical procedures, announced the publication of a US multicenter study showing that the iTind provides rapid and effective relief of symptoms through a catheter-free procedure that preserves sexual function for men with an enlarged prostate.

Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it will report financial results for the fourth quarter and full year 2020 and provide a corporate update at 4:30 p.m. ET on February 11, 2021.

Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, is pleased to announce that the United States Food and Drug Administration (FDA) has granted fast track designation to TH1902 as a single agent for the treatment of patients with sortilin positive recurrent advanced solid tumors that are refractory to standard therapy.

Novel immunotherapy approach designed to stimulate immune response by activating B cells to enhance polyclonal antibody production and potentially reduce hospitalization and progression to respiratory failure Randomized, double-blind, placebo-controlled study expected to enroll ~1,000 patients across global sites with results expected in Q4 2021 Company to host conference call and webcast today at 8:30 a.m. ET / 5:30 a.m. PT

ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products used in infusion therapy and critical care applications, today announced the time of its fourth quarter and fiscal year 2020 earnings release and conference call.

NKMax America, a biotechnology company harnessing the power of the body’s immune system through the development of Natural Killer cell therapies, announced the appointment of Stephen Chen, MBA to Chief Operating Officer.

Equillium, Inc. (Nasdaq: EQ) a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced that it has entered into a securities purchase agreement with life science institutional investment funds managed by Decheng Capital, to purchase 4,285,710 units (the “Units”) from Equillium,